Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New blood markers could spot dangerous pregnancy complication earlier

NCT ID NCT07349277

Diagnosis Sponsor: Ammar Jassim Abed Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether three substances in the blood can help doctors diagnose and monitor preeclampsia, a serious pregnancy condition involving high blood pressure. Researchers will measure these markers in 120 pregnant women between 20 and 36 weeks. The goal is to find a more accurate way to detect preeclampsia early and track how well treatment is working.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a simple blood test to detect preeclampsia earlier and more accurately, helping doctors manage the condition.
What could go wrong
This is an early-stage study with only 120 participants. The markers may not prove reliable enough for widespread use, and results may not apply to all pregnant women.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Apr 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

he study population will include pregnant women aged 18-45 years, between 20 and 36 weeks of gestation, attending the antenatal clinic at the study site. Participants will be divided into three groups: Pregnant women diagnosed with preeclampsia who have not yet received antihypertensive treatment. Pregnant women diagnosed with preeclampsia who are receiving antihypertensive treatment. Healthy pregnant women serving as control subjects. Exclusion criteria include pre-existing chronic hypertension, renal disease, diabetes mellitus, multiple gestations, or autoimmune disorders. All participants will provide informed consent before enrollment. Blood samples will be collected for biomarker analysis (sFlt-1, PlGF, soluble endoglin, and osteoprotegerin). This population has been selected to allow comparison of biomarker levels in different clinical scenarios and to evaluate their

Ages

18 to 45 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

IInclusion Criteria: * Pregnant women between 20 and 36 weeks of gestation * Age between 18 and 45 years * Attending the antenatal clinic at the study site Exclusion Criteria: * Chronic hypertension * Renal disease * Diabetes mellitus * Multiple gestations * Autoimmune disorders

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gestational hypertension are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hypertension, pregnancy-induced hypertensive disorder preeclampsia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gestational hypertension Hypertensive disorders of pregnancy Preeclampsia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Bint Al Huda Maternity Hospital

    RECRUITING

    Nasiriyah, Dhi Qar, 64001, Iraq

More trials for these conditions

Other studies related to the condition(s) this trial covers.